Type 2 Diabetes Management
Type 2 Diabetes
DevelopmentActive
Key Facts
About iWel
iWel Health is a private, pre-revenue biotech/digital health company founded in 2016, focusing on making CGM technology accessible for wellness and metabolic health management. The company is developing a disposable, smartphone-connected CGM device aimed at the large markets of weight loss (including GLP-1 users), prediabetes, and diabetes. Led by a seasoned medical device and pharmaceutical veteran, iWel is positioning itself in the competitive CGM landscape by emphasizing affordability and over-the-counter accessibility for non-traditional, consumer-led use cases.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |